Navigation Links
Concord Medical Enters into Joint Venture Agreement with Chang'An Hospital
Date:7/12/2010

BEIJING, July 12 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that effective as of July 1, 2010 it has entered into a joint venture with Chang'An Hospital for the operation of Chang'An Hospital's cancer treatment facilities by acquiring a 52% equity interest in Xi'an Wan Jie Hua Xiang Medical Technology Development Limited ("Wan Hua Tech"). Wan Hua Tech owns the land and building of Chang'An Hospital's cancer treatment facilities, which will be used for Chang'An CMS International Cancer Center (CCICC)'s future full operation. The purchase price for this acquisition is RMB103 million. Upon the acquisition, Concord Medical will be able to assume the preliminary operation of Chang'An Hospital's cancer treatment facilities to provide services to Chang'An Hospital.

During the preliminary operating period for Chang'An Hospital's cancer treatment facilities while waiting for the clinical license, the primary focus of the Chang'An Hospital's cancer treatment facilities will be on transitioning Chang'An Hospital cancer diagnosis and treatment facilities to CCICC, recruiting doctors and nurses and purchasing additional equipment. The selling equity holder of Wan Hua Tech is responsible for obtaining the clinical license, which will allow Concord Medical to provide cancer diagnosis and treatment services directly to patients.

About Concord Medical

Concord Medical operates the largest network of radiotherapy and diagnostic imaging facilities in China in terms of revenues and the total number of facilities in operation per available statistics. The Company currently operates a network of more than 89 centers spanning 37 cities and 21 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, the Company provides radiotherapy and diagnostic imaging equipments and manages the daily operations of its centers located on its hospital partners' premises. The Company provides ongoing training to doctors and other medical personnel in its network to ensure a high level of clinical care for patients.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Such factors include: the number of new radiotherapy and diagnostic imaging centers opened; the increase in the number of patients in existing centers; the establishment of specialty cancer hospitals; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government; and technological or therapeutic changes affecting the field of cancer treatment and diagnostic imaging. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    For investor and media inquiries please contact:

    China

     Stephanie Song
     Concord Medical Services
     Tel:   +86-10-5957-5287
     Email: stephanie.song@cmsholdings.com

     Lilian Wong
     Brunswick Group, LLC
     Tel:   +86-10-6566-2256
     Email: lwong@brunswickgroup.com

    U.S.

     Nicki Kahner
     Brunswick Group, LLC
     Tel:   +1-212-333-3810
     Email: nkahner@brunswickgroup.com


'/>"/>
SOURCE Concord Medical Services Holdings Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Concord Medical Files 2009 Annual Report on Form 20-F
2. Concord Medical Announces Share Repurchase Program
3. Concord Medical Announces New Centers Opening at Hospital Partner
4. Concord Medical to Report First Quarter 2010 Financial Results on Thursday, May 27, 2010
5. Concord Grape Juice Has No Significant Impact on Body Weight
6. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
7. New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
8. Dune Medical Devices Announces Positive Interim Results From EU MarginProbe™ Study Presented at German Breast Cancer Society Meeting
9. Partnership for Quality Medical Donations Commits to Long-Term Recovery in Haiti
10. ECRI Institute Adds 4,000 New Terms to Universal Medical Device Nomenclature System™
11. National Physician Staffing, Inc. Formed to Meet Current and Projected Increases in Demand for Medical Personnel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key ... to their offering. ... global pharmacogenomics market was valued at US$ 7,167.6 Mn in ... 2024, expanding at a CAGR of 5.6% from 2016 to ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Manufacturing Services Market Analysis By Service (Manufacturing, Research), By Country, ... - 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing ... 2025 Low drug registration cost in Latin American ...
(Date:4/19/2017)... -- The Mobile X-Ray product segment is the most attractive ... forecast period Mobile X-Ray segment is the largest ... devices market, which is estimated to be valued at more ... of 7% over the forecast period. Mobile X-Ray segment is ... 100 Mn in 2017 over 2016. The segment,s revenue in ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... ... PA will be attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue ... Oral Reconstruction Foundation will present its annual Global Symposium at the Fontainebleau Hotel ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, a ... systems for the treatment of Acute Ischemic Stroke (AIS), today announced it has ... the product advances towards regulatory and clinical phases. , "This is another important ...
(Date:4/23/2017)... CA (PRWEB) , ... April 23, 2017 , ... ... solutions and managed services announced the achievement of Cisco Select certification and SMB ... throughout the United States. , In earning the Select Certification, Altura ...
(Date:4/22/2017)... ... April 22, 2017 , ... PharmacyChecker.com ... can save an average of 70% when buying medication online from Canadian pharmacies ... available when purchasing from other countries. The report (chart below) compares U.S. and ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... An April ... of a pair of ancient teeth, which reveal a great deal about prehistoric ice-age ... a sharp stone may have been used to remove decayed dental matter, and that ...
Breaking Medicine News(10 mins):